Advertisement

Interventionstherapiestudien bei HIV-Infektion

  • J. R. Bogner
  • A. Matuschke
  • B. Heinrich
  • H. S. Füessl
  • F.-D. Goebel
Conference paper

Zusammenfassung

Zunächst stellt sich die Frage, welche Eigenschaften eine ideale antiretrovirale Substanz aufweisen müßte. Die Antworten klingen einfach. Folgendes müßte gewährleistet sein: Eine effektive Hemmung der Virusreplikation, nicht nur in vitro, sondern auch in vivo; eine Toxizität, die auch in einer Langzeittherapie nicht limitierend ist; eine maximale therapeutische Breite; Fehlen von Resistenzentwicklung; günstige pharmakokinetische Eigenschaften bezüglich Passage der Blut-Hirn-Schranke, Plasmahalbwertszeit und Bioverfügbarkeit bei oraler Applikation. Nicht zuletzt ist hinsichtlich des Langzeiteinsatzes idealerweise eine kostengünstige Substanz wünschenswert [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Yarchoan R, Broder S (1987) Strategies for the pharmacologic intervention against HTLV III/LAV. In: Broder S (ed) AIDS: Modern concepts and therapeutic challenges. Dekker, New York, pp 335–360Google Scholar
  2. 2.
    DeClercq E (1988) Antiviral treatment for HIV-infection. In: AIDS/HIV experimental treatment directory 2; 1–61/1988Google Scholar
  3. 3.
    Bogner JR et al (1988) Serum neopterin levels as predictor of AIDS. Klin Wochenschr 66: 1015–1018, 1988PubMedCrossRefGoogle Scholar
  4. 3a.
    Jackson GG et al. (1988) Passive imunoneutralization of HIV p24 antigenemia in patients with advanced AIDS by infusion of human plasma. Abstract 3064, IV. Int. Conf on AIDS, StockholmGoogle Scholar
  5. 4.
    Paruti DM et al. (1987) D-penicillamine (DPA) treatment for lymphadenopathy syndrome (LAS) and AIDS-related complex. Abstract TP.220; III. Int. Conf. on AIDS, WashingtonGoogle Scholar
  6. 5.
    Mitsuya H et al. (1988) Dextran sulfate suppression of viruses in the HIV family. Inhibition of virion binding to CD4+ cells. Science 240: 646–649PubMedCrossRefGoogle Scholar
  7. 6.
    Yust I et al. (1988) Reduction of circulation HIV-antigen in seropositive patients after treatment with AL 721, Abstract 3530, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  8. 7.
    Goebel F-D et al. (1988) Clinical findings after administration of lipids in AIDS. A pilot study. Abstract 3531, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  9. 8.
    Pert CB, Ruff MR (1986) Peptide T(4–8)-a pentapeptide sequence in the AIDS virus envelope which blocks infectivity is essentially conserved across 9 isolates. Clin Neuropathol 9: 482–484Google Scholar
  10. 9.
    Carteron NL et al. (1988) Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol 140: 713–716PubMedGoogle Scholar
  11. 9a.
    Weiss RA (1988) Receptor molecule blocks HIV. Nature 331:15PubMedCrossRefGoogle Scholar
  12. 10.
    Abrams DI et al. (1987) Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 14: 527–531Google Scholar
  13. 11.
    Bergdahl S et al. (1988) Antiviral effect against HIV in patients with AIDS-related complex given intermittent i.v. foscarnet. Abstract 3588, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  14. 12.
    Mansell PWA, Heseltine PNR et al. (1987) Ribavirin delays progression of the lymphadenopathy syndrome (LAS) to the acquired immunodeficiency syndrome (AIDS), Abstract T.8.5., III. Int. Conf. on AIDS, WashingtonGoogle Scholar
  15. 13.
    Yarchoan R et al. (1988) Phase I studies of 2′3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1: 76–81PubMedCrossRefGoogle Scholar
  16. 14.
    Fischl M et al. (1988) Phase I study of interferon alpha and AZT in patients with AIDS-related Kaposi’s sarcoma. Abstract 3133, IV. Int. Conf. on AIDS; StockholmGoogle Scholar
  17. 15.
    Orholm M et al. (1988) Effect on serum p24 antigen of a combination therapy with low dose interferon and zidovudine. Abstract 3626, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  18. 16.
    Bratzke B et al. (1988) Combination of interferon (ra2a-IFN) and zidovudine for the therapy of HIV-associated Kaposi-sarcoma (KS). Abstract 3631, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  19. 17.
    Ruprecht RM et al. (1988) Postexposure therapy with azidothymidin and interferon alpha prevents retro viral infection. Abstract 3632, IV. Int. Conf. on AIDS, StockholmGoogle Scholar
  20. 18.
    Seligman M (1988) Zidovudine, plus or minus acyclovir, in the treatment of AIDS patients post-opportunistic infection. Wellcome-Satelliten-Symposium, StockholmGoogle Scholar
  21. 19.
    Pizzo PA et al. (1988) Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 319: 889–896PubMedCrossRefGoogle Scholar
  22. 20.
    Calvelli TA, Rubinstein A (1986) Intravenous gamma globulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis 5: 207–210CrossRefGoogle Scholar
  23. 21.
    Brunkhorst U et al. (1988) I.v. gammaglobulin in treatment of symptomytic HIV-1 infection. Abstract 7251, IV. Int. Conf. on AIDS, StockholmGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. R. Bogner
    • 1
  • A. Matuschke
    • 1
  • B. Heinrich
    • 1
  • H. S. Füessl
    • 1
  • F.-D. Goebel
    • 1
  1. 1.MünchenDeutschland

Personalised recommendations